See all results for “”
PEPTIDE SUPERMARKET®

Mazdutide Price Comparison

Live prices from 0 SA suppliers, compared side by side so you never overpay.

GLP-1 & metabolic research
We compare prices & may earn a commission. We do not sell or supply any products. Full disclosure.

We may earn a commission from the suppliers listed here. Read our full disclosure.

0 results

No products found

We haven't found any suppliers listing this peptide yet. Check back soon as we update our database regularly.

More ways to compare Mazdutide

Different views of the same live SA pricing, tuned for how you like to shop.

Best Mazdutide Prices Best prices ranked Cheapest Mazdutide Prices Cheapest suppliers compared Where to Buy Mazdutide Full buyer's guide Buy Mazdutide Online SA Cheap Today's hottest deals Mazdutide Price Comparison Live price dashboard Mazdutide SA Supplier Verified SA supplier directory Mazdutide For Sale Browse listings for sale

Compare another peptide

PeptideSupermarket® compares prices but doesn't sell products.

All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.

We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.

By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.

Mazdutide Profile

Extensively Studied

Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes

Overview

First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.

Mechanism of Action

Dual agonist activation: GLP-1 stimulates insulin, suppresses glucagon, slows gastric emptying; Glucagon increases energy expenditure and thermogenesis while GLP-1 counteracts glucose-raising effects.

Key Benefits

  • Up to 20% body weight loss
  • Superior glycemic control versus semaglutide
  • Increased energy expenditure via glucagon receptor activation
  • Improved cardiometabolic markers (BP, lipids, liver fat)
  • Once-weekly injection convenience

Quick Stats

Typical Dose
Start 1.5-3mg weekly, titrate up to 6-9mg based on response
Frequency
Once weekly injection
Cycle Duration
48-60+ weeks for optimal results per clinical trials
Storage
Refrigerate reconstituted solution at 2-8°C, use within 30 days; lyophilized powder at -20°C until reconstitution

Molecular Information

Molecular Weight
4,563.1 Da
Length
33 amino acids
Type
Oxyntomodulin analog with fatty acid conjugation
Half-Life
6-8 days

Amino Acid Sequence

33-amino acid linear synthetic peptide

Modifications

C20 fatty diacid conjugation via hydrophilic linker at Lys20 for extended half-life

Research Indications

The following information is derived from published scientific literature and is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. These peptides are not approved for human use and are sold exclusively for in-vitro laboratory research.

Severe Obesity Management

Most Effective

GLORY-2 demonstrated 20.1% weight loss with 9mg over 60 weeks; 48.7% achieved ≥20% reduction.

Metabolic Syndrome Improvement

Most Effective

Significant reductions in waist circumference, systolic BP (-7.57 mmHg), triglycerides (-43%).

Liver Fat Reduction

Most Effective

Exploratory analysis showed 80.2% reduction in liver fat, suggesting MASLD/MASH benefits.

Glycemic Control

Most Effective

HbA1c reductions of 1.41-2.03% across trials; DREAMS-3 showed -2.03% vs semaglutide -1.84%.

Dual Endpoint Achievement

Most Effective

48% achieved HbA1c <7.0% AND ≥10% weight loss versus 21% with semaglutide.

Blood Pressure Reduction

Effective

Systolic reduction of -7.57 mmHg, diastolic -2.98 mmHg in clinical trials.

Lipid Profile Enhancement

Effective

Total cholesterol -16.82%, triglycerides -43.29%, LDL -17.07%.

Dosing Protocols

injectable

Subcutaneous injection delivering dual GLP-1/glucagon agonism with once-weekly dosing enabled by fatty acid conjugation.

Goal Dose Frequency Route
Weight loss initiation (3mg target) 1.5mg → 3mg Once weekly SubQ
Weight loss progression (4.5mg target) 1.5mg → 3mg → 4.5mg Once weekly SubQ
Weight loss optimization (6mg target) 2mg → 4mg → 6mg Once weekly SubQ
Maximum weight loss (9mg target) 3mg → 6mg → 9mg Once weekly SubQ
T2D management (mild-moderate) 3-4.5mg weekly Once weekly SubQ

Key Tips

  • Once-weekly injection convenience
  • Proven efficacy in Phase 3 trials
  • Superior results versus semaglutide
Materials Needed
Mazdutide lyophilized powder vial Bacteriostatic water (BAC) for injection Insulin syringes (29-31 gauge) Alcohol prep pads Refrigerator (2-8°C)
Steps
  1. 1 Allow vial to reach room temperature (15-20 minutes)
  2. 2 Clean vial top with alcohol swab, air dry completely
  3. 3 Calculate reconstitution volume for desired concentration
  4. 4 Draw bacteriostatic water into syringe, remove air bubbles
  5. 5 Inject BAC water slowly down vial side—drop by drop to prevent foaming
  6. 6 Gently swirl vial in circular motion
  7. 7 Verify complete clarity and colorless appearance
  8. 8 Label vial with reconstitution date and concentration
  9. 9 Store at 2-8°C, use within 30 days

Peptide Interactions

Semaglutide

Avoid

Both are GLP-1 agonists; combining increases hypoglycemia and severe GI side effect risk.

Tirzepatide

Avoid

Both target GLP-1 receptor; additive effects on GI symptoms and hypoglycemia risk.

Liraglutide

Avoid

Another GLP-1 agonist; dual therapy contraindicated due to additive receptor activation.

Insulin

Monitor

May require significant dose reduction due to improved glucose control; monitor for hypoglycemia.

Sulfonylureas

Monitor

Increased hypoglycemia risk; dose reduction may be necessary.

Metformin

Synergistic

Complementary mechanisms; clinical trials allowed stable metformin use with enhanced efficacy.

BPC-157

Compatible

No known interactions; may support gut health and potentially reduce GI side effects.

Oral Contraceptives

Monitor

Delayed gastric emptying may affect absorption; separate administration by 1 hour.

What to Expect

Week 1-2

Appetite reduction, possible mild nausea, decreased portion sizes

Week 3-4

Early weight loss begins (1-2%), improved satiety after meals

Week 4-8

Dose escalation phase, GI symptoms typically improving, 3-5% weight loss

Week 8-16

Steady weight loss continues (7-12%), energy expenditure effects evident

Week 16-32

Significant weight reduction (12-17%), metabolic markers improving

Week 32-60

Peak effects (up to 20% weight loss), sustained improvements in BP, lipids, glucose

Side Effects & Safety

Common Side Effects

  • Nausea (mild-moderate, typically improves over time)
  • Diarrhea
  • Vomiting
  • Increased heart rate (5-17 bpm observed)

Monitoring

  • Start with lowest dose, escalate gradually every 4 weeks
  • Monitor blood glucose if taking insulin or sulfonylureas
  • Watch for pancreatitis symptoms
  • Monitor thyroid function
  • Maintain adequate hydration during initial weeks

Stop Signs

  • Severe or persistent abdominal pain (potential pancreatitis)
  • Neck lumps, hoarseness, or difficulty swallowing
  • Severe nausea/vomiting preventing adequate nutrition or hydration
  • Signs of severe hypoglycemia (confusion, sweating, shakiness)
  • Severe allergic reactions (rash, difficulty breathing, facial swelling)
  • Unusual mood changes, depression, or suicidal thoughts
  • Signs of gallbladder problems (severe upper right abdominal pain)

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • MEN2 syndrome history (class warning for GLP-1 agonists)
  • Pregnancy or breastfeeding (insufficient safety data)

Quality Checklist

Good Signs

  • White to off-white lyophilized powder without clumping or discoloration
  • Completely clear and colorless appearance after reconstitution—no visible particles
  • Intact vial seal and clear labeling with mg dosage, batch numbers, expiration dates

Warning Signs

  • Source verification critical—available from research chemical suppliers

Bad Signs

  • Clumping, discoloration, or moisture in powder
  • Persistent cloudiness or particles after reconstitution indicates degradation

Research & References

Key References

  1. 2025

    GLORY-1 Phase 3 Trial

    610 Chinese adults with obesity/overweight; 48 weeks. First Phase 3 weight management trial showing clinically meaningful weight reductions. NEJM.

  2. 2025

    GLORY-2 Phase 3 Trial

    462 Chinese adults with obesity; 60 weeks; 9mg dose. 20.1% weight loss vs 2.8% placebo; 48.7% achieved ≥20% reduction; no plateau observed.

  3. 2025

    DREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide

    349 Chinese adults with T2D and obesity; 32 weeks. Mazdutide superiority: 48% vs 21% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001).

  4. 2024

    Phase 2 T2D Trial

    Chinese adults with T2D; 20 weeks. HbA1c reductions 1.41-1.67% vs 0.03% placebo; weight loss up to 7.1%. Diabetes Care.

Search PubMed for Mazdutide

Get Peptide Price-drop Alerts

Be the first to know when prices drop on your favourite peptides

No spam. Unsubscribe anytime. We respect your privacy.